These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 36436305)
1. Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge. Sun S; Li E; Zhao G; Tang J; Zuo Q; Cai L; Xu C; Sui C; Ou Y; Liu C; Li H; Ding Y; Li C; Lu D; Zhang W; Luo P; Cheng P; Gao Y; Tu C; Pitard B; Rosenecker J; Wang B; Liu Y; Zou Q; Guan S Biomaterials; 2023 Jan; 292():121907. PubMed ID: 36436305 [TBL] [Abstract][Full Text] [Related]
3. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract. Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008 [TBL] [Abstract][Full Text] [Related]
4. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842 [TBL] [Abstract][Full Text] [Related]
5. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2022; 13():995235. PubMed ID: 36172368 [TBL] [Abstract][Full Text] [Related]
6. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice. Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572 [TBL] [Abstract][Full Text] [Related]
7. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381 [TBL] [Abstract][Full Text] [Related]
9. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224 [TBL] [Abstract][Full Text] [Related]
10. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP Front Immunol; 2021; 12():781280. PubMed ID: 34987509 [TBL] [Abstract][Full Text] [Related]
11. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection. Americo JL; Cotter CA; Earl PL; Liu R; Moss B Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343 [TBL] [Abstract][Full Text] [Related]
12. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. Cokarić Brdovčak M; Materljan J; Šustić M; Ravlić S; Ružić T; Lisnić B; Miklić K; Brizić I; Pribanić Matešić M; Juranić Lisnić V; Halassy B; Rončević D; Knežević Z; Štefan L; Bertoglio F; Schubert M; Čičin-Šain L; Markotić A; Jonjić S; Krmpotić A Eur J Immunol; 2022 Jun; 52(6):936-945. PubMed ID: 35304741 [TBL] [Abstract][Full Text] [Related]
13. Induction of systemic, mucosal, and cellular immunity against SARS-CoV-2 in mice vaccinated by trans-airway with a S1 protein combined with a pulmonary surfactant-derived adjuvant SF-10. Kimoto T; Sakai S; Kameda K; Morita R; Takahashi E; Shinohara Y; Kido H Influenza Other Respir Viruses; 2023 Mar; 17(3):e13119. PubMed ID: 36909295 [TBL] [Abstract][Full Text] [Related]
14. Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants. Liao G; Lau H; Liu Z; Li C; Xu Z; Qi X; Zhang Y; Feng Q; Li R; Deng X; Li Y; Zhu Q; Zhu S; Zhou H; Pan H; Fan X; Li Y; Li D; Chen L; Ke B; Cong Z; Lv Q; Liu J; Liang D; Li A; Hong W; Bao L; Zhou F; Gao H; Liang S; Huang B; Wu M; Qin C; Ke C; Liu L Virol J; 2022 Dec; 19(1):212. PubMed ID: 36494863 [TBL] [Abstract][Full Text] [Related]
15. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine. Pitcovski J; Gruzdev N; Abzach A; Katz C; Ben-Adiva R; Brand-Shwartz M; Yadid I; Ratzon-Ashkenazi E; Emquies K; Israeli H; Haviv H; Rapoport I; Bloch I; Shadmon R; Eitan Z; Eliahu D; Hilel T; Laster M; Kremer-Tal S; Byk-Tennenbaum T; Shahar E Vaccine; 2022 Feb; 40(8):1098-1107. PubMed ID: 35078662 [TBL] [Abstract][Full Text] [Related]
16. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. Chen L; Zhang H; Li M; Wu B; Zhang Z; Gong R Front Immunol; 2022; 13():1005321. PubMed ID: 36466882 [TBL] [Abstract][Full Text] [Related]